Sera Prognostics director Mirza sells $562 in shares

Published 05/08/2025, 23:22
Sera Prognostics director Mirza sells $562 in shares

Director of Sera Prognostics (NASDAQ:SERA), Mirza Mansoor Raza, sold 225 shares of Class A Common Stock on August 5, 2025, at a price of $2.5, for a total transaction value of $562. The transaction comes as the stock trades near $2.45, down over 15% in the past week and showing significant volatility. According to InvestingPro analysis, the company appears undervalued at current levels, while maintaining a stronger cash position than debt on its balance sheet.

The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units, as per a pre-arranged "sell to cover" arrangement mandated by Sera Prognostics. Following the transaction, Mirza Mansoor Raza directly owns 58,702 shares of Sera Prognostics, representing a stake in the company’s $92.68 million market capitalization. Get deeper insights into SERA’s insider trading patterns and 8 additional key metrics with InvestingPro’s comprehensive research report.

In other recent news, Sera Prognostics reported its first-quarter 2025 earnings, revealing a narrower-than-expected loss. The company posted an earnings per share (EPS) of -$0.20, surpassing analysts’ forecast of -$0.27. However, revenue was reported at $38,000, which fell short of the anticipated $200,000 but marked an increase from zero revenue in the same quarter of the previous year. In addition to the earnings report, Sera Prognostics has made significant leadership changes. Lee Anderson was appointed as the new Chief Commercial Officer, bringing over 30 years of healthcare leadership experience. His previous roles at Genomic Health and Exact Sciences (NASDAQ:EXAS) were noted for contributing to revenue growth and successful product launches. Furthermore, Sera Prognostics held its annual stockholders meeting, where Jane F. Barlow, M.D., and Mansoor Raza Mirza, M.D., were elected as Class I directors for a three-year term. The company also ratified its auditor during this meeting.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.